WallStreetZenWallStreetZen

NASDAQ: GELS
Gelteq Ltd Stock

Overview
EarningsRevenueDividendOwnership
$1.20-0.02 (-1.64%)
Updated Oct 29, 2025
GELS Price
$1.20
Fair Value Price
-$0.27
Market Cap
$11.33M
52 Week Low
$0.77
52 Week High
$5.50
P/E
N/A
P/B
0.92x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.34
Operating Cash Flow
N/A
Beta
2.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GELS Overview

Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GELS's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
GELS
RankedUnranked of 56

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Ironwood Pharmaceuticals (IRWD)
$1.51A
Amneal Pharmaceuticals (AMRX)
$10.43A
Neurocrine Biosciences (NBIX)
$138.02A
View Top Pharmaceutical Stocks

Be the first to know about important GELS news, forecast changes, insider trades & much more!

GELS News

Overview

Due Diligence Score

–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GELS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GELS ($1.20) is overvalued by 548.07% relative to our estimate of its Fair Value price of -$0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GELS ($1.20) is not significantly undervalued (548.07%) relative to our estimate of its Fair Value price of -$0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GELS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more GELS due diligence checks available for Premium users.

Valuation

GELS fair value

Fair Value of GELS stock based on Discounted Cash Flow (DCF)

Price
$1.20
Fair Value
-$0.27
Undervalued by
548.07%
GELS ($1.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GELS ($1.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

GELS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.92x
Industry
2.22x
GELS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GELS's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%

Assets to liabilities

Assets
$15.6M
Liabilities
$3.9M
Debt to equity
0.34
GELS's short-term liabilities ($4.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GELS's short-term assets ($3.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GELS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

GELS vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GELS–$11.33M-1.64%N/A0.92x
BFRI–$11.31M0.00%-0.57x-2.42x
TXMD–$14.00M-3.20%-30.25x0.51x
YCBD–$8.47M-7.77%-0.27x1.39x
SBFM–$8.02M-4.35%0.39x0.31x
View Top Pharmaceutical Stocks

Gelteq Stock FAQ

What is Gelteq's quote symbol?

(NASDAQ: GELS) Gelteq trades on the NASDAQ under the ticker symbol GELS. Gelteq stock quotes can also be displayed as NASDAQ: GELS.

If you're new to stock investing, here's how to buy Gelteq stock.

What is the 52 week high and low for Gelteq (NASDAQ: GELS)?

(NASDAQ: GELS) Gelteq's 52-week high was $5.50, and its 52-week low was $0.77. It is currently -78.18% from its 52-week high and 55.84% from its 52-week low.

How much is Gelteq stock worth today?

(NASDAQ: GELS) Gelteq currently has 9,438,075 outstanding shares. With Gelteq stock trading at $1.20 per share, the total value of Gelteq stock (market capitalization) is $11.33M.

Gelteq stock was originally listed at a price of $2.94 in Oct 29, 2024. If you had invested in Gelteq stock at $2.94, your return over the last 1 years would have been -59.18%, for an annualized return of -59.18% (not including any dividends or dividend reinvestments).

How much is Gelteq's stock price per share?

(NASDAQ: GELS) Gelteq stock price per share is $1.20 today (as of Oct 29, 2025).

What is Gelteq's Market Cap?

(NASDAQ: GELS) Gelteq's market cap is $11.33M, as of Oct 30, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gelteq's market cap is calculated by multiplying GELS's current stock price of $1.20 by GELS's total outstanding shares of 9,438,075.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.